IO Biotech, Inc. (NASDAQ:IOBT) Receives Consensus Rating of “Reduce” from Analysts
Analysts Set IO Biotech, Inc. (NASDAQ:IOBT) PT at $6.33
IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decline in Short Interest
Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom Fishing
Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Grows By 47.2%
IO Biotech Provides Corporate Update
IO Biotech Announces Exploration of Strategic Alternatives
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
IO Biotech Announces Participation in Upcoming December Investor Conferences
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why
IO Biotech, Inc. (NASDAQ:IOBT) Receives Average Rating of “Hold” from Analysts
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
IO Biotech Provides Update Following Pre-BLA Meeting with FDA
IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know
IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights
IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma
IO Biotech's cancer vaccine shows improvement in late-stage study goal
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?
IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference
IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025
IO Biotech Reports 2024 Business Highlights
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
IO Biotech to Present at the 45th Annual Cowen Health Care Conference
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights
3 Penny Stocks with 190% Growth Potential According to Wall Street Analysts
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
IO Biotech to Present at Jefferies Global Healthcare Conference